Skip to main content

Table 8 Sample classification after LDA to discriminate between CSF samples from patients with Relapse–remitting multiple sclerosis (RRMS) and non-inflammatory diseases of the CNS (N-INF) based on the identified protein spots

From: Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis

  Classification resultsb,c
Disease Predicted Group Membership Total
RRMS N-INF
Original
 Count RRMS 67 2 69
N-INF 12 30 42
 % RRMS 97.1 2.9 100
N-INF 28.6 71.4 100
Cross-validateda
 Count RRMS 67 2 69
N-INF 14 28 42
 % RRMS 97.1 2.9 100
N-INF 33.3 66.7 100
  1. aCross validation is done only for those cases in the analysis. In cross validation, each sample is classified by the functions derived from all samples other than the one under analysis
  2. b87.4% of original grouped cases correctly classified
  3. c85.6% of cross-validated grouped cases correctly classified